Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 7/20 | 0.73 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.73 |
| ▸ | CRHBP | P24387 | 1/20 | 0.73 |
| ▸ | CASP7 | P55210 | 1/20 | 0.73 |
| ▸ | CASP6 | P55212 | 1/20 | 0.73 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.73 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.73 |
| ▸ | VKORC1 | Q9BQB6 | 2/20 | 0.72 |
| ▸ | TOP1 | P11387 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL310481 | 0.90 | VKORC1 (0.82) | NQO1CYP2C9CRHBPCASP7CASP6 | |
| SCHEMBL32659670 | 0.90 | VKORC1 (0.82) | NQO1CYP2C9CRHBPCASP7CASP6 | |
| SCHEMBL14078663 | 0.87 | CYP2C9 (0.72) | NQO1CYP2C9CRHBPCASP7CASP6 | |
| SCHEMBL18126686 | 0.86 | NQO1 (0.78) | NQO1CYP2C9CRHBPCASP7CASP6 | |
| SCHEMBL14172134 | 0.85 | NQO1 (0.68) | NQO1CYP2C9CRHBPCASP7CASP6 | |
| SCHEMBL4390609 | 0.85 | NQO1 (1.00) | NQO1CYP2C9CRHBPCASP7CASP6 | |
| SCHEMBL28761758 | 0.84 | VKORC1 (0.69) | NQO1CYP2C9CRHBPCASP7CASP6 | |
| SCHEMBL7349603 | 0.84 | VKORC1 (1.00) | NQO1CYP2C9CRHBPCASP7CASP6 | |
| SCHEMBL5730839 | 0.84 | CYP2C9 (0.56) | NQO1CYP2C9CRHBPCASP7CASP6 | |
| SCHEMBL7072964 | 0.84 | NQO1 (0.60) | NQO1CYP2C9CRHBPCASP7CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | disclosed |
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | DRUZGALA PASCAL | 2008-09-11 | — | — | US | disclosed |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | ARYX THERAPEUTICS, INC. | 2007-06-07 | — | — | US | disclosed |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | ARYX THERAPEUTICS, INC. | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221204-A1 | Materials and Methods for Treating Coagulation Disorders | CES1, F2, CYP3A5 | NQO1 249/4885CYP2C9 24/4885CRHBP 2941/4885 |
| US-20070129429-A1 | Materials And Methods For Treating Coagulation Disorders | CES1, F2, CYP3A5 | NQO1 249/4885CYP2C9 24/4885CRHBP 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.